Latest news with #NationalBiotechnologyStrategy
CairoScene
4 days ago
- Health
- CairoScene
Over 25 Saudi Health Groups Spotlight Biotech Innovation at BIO Boston
Saudi Arabia's national pavilion at BIO 2025 features over 25 groups in health and science, spotlighting research potential and global biotech partnerships from June 16th to the 19th in Boston. Saudi Arabia is participating in the 2025 BIO International Convention in Boston with a national pavilion led by the Ministry of Health. The Kingdom's delegation includes more than 25 organisations from across the government, private sector, and research community, marking one of its largest representations at the global biotech summit to date. The delegation is taking part in exhibitions and high-level meetings focused on advancing biotechnology research, development, and investment. The event, widely recognised as the world's largest gathering of stakeholders in life sciences and medical innovation, runs through June 19th. Saudi Arabia's presence aligns with its recently launched National Biotechnology Strategy, a key pillar of the country's broader push to expand its role in science, medicine, and high-tech industries. The strategy forms part of Saudi Vision 2030, which outlines major health sector transformation programmes and aims to position the Kingdom as a global hub for innovation. The BIO Convention, hosted this year in Boston—a major centre for life sciences—offers a strategic platform for the Kingdom to showcase its advancements and attract international collaboration in emerging biotech fields.
Yahoo
4 days ago
- Business
- Yahoo
King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh
Unveiled at BIO 2025 in Boston, the project marks a major step toward Saudi Arabia's goal to become a global biotechnology hub by 2040. BOSTON, June 17, 2025 /PRNewswire/ -- BIO International Convention 2025 -- At the BIO International Convention 2025 in Boston, King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus. The new facility will be located at KFSHRC's main campus in Riyadh and will serve as a critical milestone in advancing Vision 2030 and the National Biotechnology Strategy, two national initiatives aimed at transforming the Kingdom into a global hub for life sciences, biomanufacturing, and to become a global biotech hub by 2040. "This initiative marks a historic milestone, not just for our institution, but for the Kingdom of Saudi Arabia in alignment with Vision 2030 and the National Biotechnology Strategy," said His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. "With Germfree as our partner, we are creating a world-class advanced therapies campus that will accelerate access to transformative treatments, draw the brightest minds in science, and strengthen Saudi Arabia's position as a global leader in biotechnology. This fast-track, strategic project represents a continuation of the long history of healthcare innovation that has been realized by King Faisal Specialist Hospital and Research Centre." "KFSHRC's leadership and vision align with Germfree's mission to expand access to complex therapies through future-proofed, agile infrastructure," said Kevin Kyle, CEO of Germfree Laboratories. "Together, we are building much more than a facility for Cell & Gene Therapy manufacturing, we're building a turnkey, scalable platform for discovery and delivery of curative therapies for the people of Saudi Arabia, the Middle East, and beyond. This collaboration reflects the critical role infrastructure plays in unlocking access to advanced therapies, and we are proud to support KFSHRC's vision for patient-centric care." Under the terms of a signed Letter of Intent, the turnkey project will fast-track the Kingdom's ability to manufacture cell and gene therapies locally, host international clinical trials, and attract leading pharmaceutical partnerships and scientific talent from around the world. Driving Saudi Arabia's Vision for Global Biotech Leadership This project directly supports Saudi Arabia's National Biotechnology Strategy, launched to localize vaccine and therapeutic production, develop sovereign biomanufacturing capabilities, and establish the Kingdom as a global biotechnology leader by 2040. As a core pillar of Vision 2030, the strategy aims to make Saudi Arabia a destination for clinical trials, scientific discovery, pharmaceutical investment, and biotech entrepreneurship across the Middle East and beyond. By establishing a globally competitive manufacturing campus, KFSHRC is not only advancing national healthcare; it is setting a new global standard for innovation, scalability, and patient-centered care. A Smart, Scalable Biomanufacturing Platform The ATMP Manufacturing Campus will be delivered as a fully CGMP-compliant, off-site built, modular solution, developed in strategic phases to support immediate clinical impact and long-term growth. The project will begin with the deployment of Germfree's BioGO® Box single-module cleanroom solution, enabling early operator training, tech transfer, and R&D activities. In parallel, a newly constructed facility will be built centrally on the KFSHRC campus to house prefabricated modular cleanroom clusters, providing 16 production suites, each designed for multi-modal CGT production supporting both clinical and commercial-scale manufacturing. Full operational readiness will be reached just 18 months after contract signing, roughly half the timeline of a conventional stick-built facility of comparable scope. That speed, combined with the flexibility to scale or repurpose suites as new therapies emerge, means Saudi patients will gain access to advanced treatments years sooner than traditional construction would allow. The state-of-the-art facility will meet SFDA, FDA, EMA, and BMBL requirements and will include a fully integrated digital manufacturing platform designed to support smart, data-driven CGMP operations from day one. Germfree's continued growth is supported by EW Healthcare Partners, a leading private equity company that makes growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and Europe. About King Faisal Specialist Hospital & Research Centre (KFSHRC) King Faisal Specialist Hospital & Research Centre is Saudi Arabia's foremost tertiary-and-quaternary referral institution, delivering world-class care in oncology, transplantation, cardiovascular medicine and precision therapeutics. It is ranked No. 1 in the Middle East & Africa and 15th globally among academic medical centers by Brand Finance's 2025 report and is listed on Newsweek's World's Best Hospitals as well as World's Best Smart Hospitals 2025. As a flagship partner in the Kingdom's Vision 2030 and National Biotechnology Strategy an initiative to localize biomanufacturing and make Saudi Arabia a global biotech hub by 2040, KFSHRC forges international collaborations, drives cutting-edge clinical research, and cultivates Saudi scientific talent to expand patient access to life-changing therapies. About Germfree Laboratories Germfree advances ATMP development and point-of-care manufacturing by delivering U.S-designed and built, ready-to-operate modular and mobile CGMP cleanrooms, integrated equipment, and lifecycle services under a single contract. Today, more than 200 Germfree laboratories, cleanrooms, and complex equipment systems operate in 32 countries, underscoring the company's commitment to innovative, agile, integrated, and impactful research and biomanufacturing worldwide. Strategic partnerships with process-technology leaders and in-country service firms ensure every deployment arrives fully validated, operationally ready, and regulatory compliant from day one. The company's U.S. manufacturing hub and on-site service programs ensure rapid deployment, sustained performance, knowledge transfer to local workforces and a continuous pipeline of innovation that keeps facilities future ready as advanced therapies evolve. View original content to download multimedia: SOURCE Germfree Laboratories LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Leaders
4 days ago
- Health
- Leaders
Saudi Arabia Participates in BIO 2025 in Boston
A Saudi delegation is currently taking part in the 2025 BIO International Convention with the participation of over 25 government and private entities, according to the Saudi Press Agency. Led by the Saudi Health Ministry, the Saudi pavilion aims basically to highlight the objectives of the National Biotechnology Strategy launched by the Saudi Crown Prince Mohammed bin Salman. The event provides Saudi Arabia with an exclusive opportunity to showcase its investment opportunities and unparalleled research capabilities. Headed by Deputy Minister of Health for Planning and Development Eng. Abdulaziz Al-Rumaih, the pavilion features several national initiatives in biotechnology and scientific research. Therefore, it stands as a testament to the Kingdom's dedication to encouraging health innovation and boosting investment in clinical research and biotech. Importantly, the participation fosters the Saudi Arabia's efforts to achieve the objectives of the Health Sector Transformation Program outlined by the Saudi Vision 2030. The 2030 vision seeks primarily to establish a vibrant society, a thriving economy, as well as a sustainable, healthy future. Held from June 16 to 19 at the Boston Convention & Exhibition Center, the 2025 BIO International Convention represents the world's leading event for the biotechnology industry. Related Topics: Saudi Crown Prince Launches National Biotechnology Strategy Opening of Riyadh Global Medical Biotechnology Summit World's First De-extinction: Dire Wolf is Back After 10,000 Years Short link : Post Views: 24 Related Stories
Mid East Info
04-06-2025
- Business
- Mid East Info
KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region - Middle East Business News and Information
As part of Saudi Arabia's broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its role as the Kingdom's leading Clinical Trials hub in 2024 — conducting 52.4% of all active Clinical Trials nationwide, according to the Saudi National Institute of Health. This milestone reflects the sustained success of KFSHRC's Clinical Trials Transformation Initiative, launched in 2021 to build an integrated, patient-centered research ecosystem. By the end of 2024, the hospital had recorded 701 active research proposals, representing an 8% increase over the previous year. In Riyadh alone, research approvals rose by 20%, demonstrating growing alignment between scientific discovery and clinical care delivery. KFSHRC's research growth was matched by key innovation milestones. In 2024, it became the first in Saudi Arabia to locally produce CAR-T cells — a major step toward national self-sufficiency in advanced therapies. It also delivered a breakthrough in hemophilia care, using one-time gene therapy to restore clotting function in eight patients, eliminating preventive treatment and significantly improving quality of life. These advancements align closely with Saudi Arabia's Vision 2030 and National Biotechnology Strategy, which designate biotechnology as a national priority sector — aiming to localize therapeutic development, accelerate innovation, and establish global leadership by 2040. Complementing its scientific leadership, KFSHRC has also invested in public engagement, launching awareness campaigns in high-traffic public venues to promote Clinical Trials literacy and reduce misconceptions around participation. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally among the world's top 250 Academic Medical Centres for the third consecutive year, and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Business Upturn
04-06-2025
- Business
- Business Upturn
KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region
RIYADH, Saudi Arabia, June 04, 2025 (GLOBE NEWSWIRE) — As part of Saudi Arabia's broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its role as the Kingdom's leading Clinical Trials hub in 2024 — conducting 52.4% of all active Clinical Trials nationwide, according to the Saudi National Institute of Health. This milestone reflects the sustained success of KFSHRC's Clinical Trials Transformation Initiative, launched in 2021 to build an integrated, patient-centered research ecosystem. By the end of 2024, the hospital had recorded 701 active research proposals, representing an 8% increase over the previous year. In Riyadh alone, research approvals rose by 20%, demonstrating growing alignment between scientific discovery and clinical care delivery. KFSHRC's research growth was matched by key innovation milestones. In 2024, it became the first in Saudi Arabia to locally produce CAR-T cells — a major step toward national self-sufficiency in advanced therapies. It also delivered a breakthrough in hemophilia care, using one-time gene therapy to restore clotting function in eight patients, eliminating preventive treatment and significantly improving quality of life. These advancements align closely with Saudi Arabia's Vision 2030 and National Biotechnology Strategy, which designate biotechnology as a national priority sector — aiming to localize therapeutic development, accelerate innovation, and establish global leadership by 2040. Complementing its scientific leadership, KFSHRC has also invested in public engagement, launching awareness campaigns in high-traffic public venues to promote Clinical Trials literacy and reduce misconceptions around participation. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally among the world's top 250 Academic Medical Centres for the third consecutive year, and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit or contact our media team at [email protected]. A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
